KLIMAS, Filip, ZATŁOKA-MAZUR, Dorota, RUSIŃSKI, Kacper, ZAJĄC, Piotr, PAWŁOWSKI, Bartosz, SIENKIEWICZ, Michal, POTOCZEK, Adriana, ZIĘBA, Zuzanna and PUDEŁKO, Iwona. Fungal Infections: Epidemiology, Clinical Challenges, and Advances in Diagnosis and Treatment - a review. Quality in Sport. 2025;38:57928. eISSN 2450-3118.
https://doi.org/10.12775/QS.2025.38.57928
https://apcz.umk.pl/QS/article/view/57928

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 18.01.2025. Revised: 12.02.2025. Accepted: 14.02.2025 Published: 17.02.2025.

Fungal Infections: Epidemiology, Clinical Challenges, and Advances in Diagnosis and Treatment- a review

Filip Klimas, Dorota Zatłoka-Mazur, Kacper Rusiński, Piotr Zając, Bartosz Pawłowski, Michał Sienkiewicz, Adriana Potoczek, Zuzanna Zięba, Iwona Pudełko

1. Filip Klimas
SP ZOZ MSWiA Hospital in Kraków, Kronikarza Galla 25 street,
30-053 Kraków
e1filipklimas@gmail.com
https://orcid.org/0009-0000-5266-8676

2. Dorota Zatłoka-Mazur
Tytus Chałubiński Regional Hospital in Zakopane,
Kamieniec 10 street, 34-500 Zakopane
zdorota811@gmail.com
https://orcid.org/0009-0003-3663-1891

3. Kacper Rusiński,
University Clinical Hospital in Poznan,
Przybyszewskiego Street 49, 60-355 Poznań
kacper.rusinski1@gmail.com
https://orcid.org/0009-0005-4002-9267

4. Piotr Zając
Upper Silesian Medical Center of Prof. Leszek Giec of the Silesian Medical University, Ziołowa 45-47, 40-635 Katowice – Ochojec
piotr512pz@gmail.com
https://orcid.org/0009-0004-1516-8487

5. Bartosz Pawłowski
University Clinical Hospital No. 4 in Lublin Doktora Kazimierza Jaczewskiego Street 8, 20-954 Lublin
bartek4245@gmail.com
https://orcid.org/0009-0009-3515-1777

6. Michał Sienkiewicz
Regional Specialist Hospital in Biała Podlaska Terebelska Street 57/65,
21-500 Biała Podlaska
michal.sienkiewicz09@gmail.com
https://orcid.org/0009-0001-0427-9198

7. Adriana Potoczek
University Clinical Hospital in Katowice, Medyków 14 street, 40-752 Katowice
adriana.potoczek@interia.pl
https://orcid.org/0009-0002-3981-3490

8. Zuzanna Zięba,
University Clinical Hospital in Poznan,
Przybyszewskiego Street 49, 60-355 Poznań
E-mail: zuzia1997.z@gmail.com
https://orcid.org/0009-0002-1576-8058

9. Iwona Pudełko
University Clinical Hospital in Wrocław, Borowska 213 street,
50-556 Wrocław
i.pudelko.97@gmail.com
https://orcid.org/0009-0001-6403-4141

Abstract
Fungal infections are a serious public health threat, affecting a wide variety of populations worldwide. This review presents the current state of knowledge on fungal infections, focusing on epidemiology, etiology, clinical manifestations, and emerging trends. Findings are based on 35 peer-reviewed studies and focus on both well-known and emerging fungal pathogens, diagnostic advances, and therapeutic challenges. In addition, this review emphasizes the role of environmental and social factors in shaping the dynamics of fungal disease and highlights the importance of a global, multidisciplinary effort to combat the rise in fungal disease.

The literature for this review was collected from PubMed and Google Scholar using the key words “fungal infections” combined with “epidemiology”, “etiology”, “risk factors”, “symptoms”, “complications”, “treatment”, and “trends”.

Keywords: fungal infections, epidemiology, risk factors

Introduction

Fungal infections, also known as mycoses, are caused by various groups of microorganisms, including common yeasts and molds as well as rare but deadly fungi. It is estimated that there are between 1.5 and 5 million species of fungi on the planet, but only a few hundred cause disease in humans and only a small proportion infect healthy people [1]. Fungal infections are usually not a major problem in people with a normally functioning immune system. However, they are a serious threat, especially for people with weakened immune systems, such as those undergoing chemotherapy, organ transplant recipients and patients suffering from HIV infection or AIDS [2,3]. In recent years, the incidence of fungal infections has increased rapidly due to the aging population, widespread use of immunosuppressive therapies and environmental changes. This review reviews the current literature on fungal infections to identify epidemiologic trends, clinical manifestations, advances in treatment strategies and areas of not achieved clinical need.

Materials and Methods

This review aims to investigate the current state of knowledge regarding the prevalence of fungal infections, considering the latest treatment options. The article is based on information derived from publications available in PubMed databases. The search was conducted using the keywords "fungal infections," "epidemiology," "pathogenesis," "risk factors," "symptoms," "complications," "treatment," and "trends." The gathered materials were used to create a review of essential information on the occurrence of fungal infections and to discuss the latest management and treatment methods. The analysis was based on a comprehensive review of diverse sources and relevant studies.

Epidemiology of Fungal Infections

The prevalence of fungal infections is rising, and the most commonly found pathogens are Aspergillus and Candida [4,5]. The importance of Candida in bloodstream infections, a major source of morbidity and mortality among hospitalized patients, is highlighted in a research by Pfaller and Diekema [6]. In a similar vein, Aspergillus species are important contributors to invasive lung infections, especially in recipients of bone marrow transplants [7].

Additionally, emerging infections as Mucorales and Fusarium are becoming more significant in immunocompromised populations [8]. Despite being uncommon, fusarium infections have a significant death rate since there are few treatment options and a delayed diagnosis. The prevalence of fungal infections is significantly influenced by geographic factors. In the United States, for instance, histoplasmosis is endemic in areas such as the Ohio and Mississippi River valleys, where soils supplemented with bat or bird droppings encourage the growth of fungi [9].

Significant differences exist in the prevalence and management of fungal infections when viewed globally. For example, in sub-Saharan Africa, where AIDS is quite common, cryptococcal meningitis is a major cause of AIDS-related deaths. Treatment results are harmed by delayed diagnosis and restricted access to antifungal medicines because of the low quality of healthcare in this area. 15 - 20% of AIDS-related mortality globally are caused by cryptococcal meningitis [25]. In the meantime, the increase in tropical fungal infections like Penicillium marneffei in Southeast Asia highlights the connection between population vulnerability and environmental exposure [26].

Clinical Manifestations

Fungal infections have a very wide range of clinical manifestations, from minor skin infections to serious, potentially lethal invasive illnesses. Dermatophytosis is one of the most prevalent superficial fungal infections that usually affects the skin, hair, or nails [12]. Since fungus like warm, humid conditions, these infections are especially prevalent in public areas. For instance, Detandt and Nolard [10] emphasized how important public spaces like swimming pools are in aiding the spread of dermatophytes. Because they are specialized in keratin metabolism, these organisms readily colonize both individuals and surfaces, resulting in extensive occurrences in particular populations. Subtropical swimming pools in Belgium have significantly higher dermatophyte contamination than traditional pools due to higher visitor numbers, complex construction, and longer hours. Predominant species were *Trichophyton mentagrophytes var. interdigitale* and *T. Rubrum* [10].

On the other hand, the category of invasive fungal infections (IFIs) is far more dangerous and can be lethal. People with compromised immune systems are more likely to contract infections like invasive aspergillosis. Particularly at risk are patients receiving rigorous treatments like chemotherapy or hematopoietic stem cell transplants [11]. These treatments' immunosuppressive effects, along with environmental exposure to fungal spores, provide the perfect environment for fungal diseases to infiltrate deep tissues and organs. The substantial death rate linked to invasive aspergillosis emphasizes how urgently focused antifungal treatment and early detection are needed.

Chronic mucocutaneous candidiasis (CMC), a different but no less alarming type of fungal infection, is typified by persistent and frequently resistant infections brought on by Candida species. This disorder frequently results from underlying immunological dysfunctions that affect the body's capacity to regulate the growth of fungi. For instance, invasive fungal infections (IFIs) remain a major cause of death in patients with chronic granulomatous disease (CGD). It has been demonstrated that genetic abnormalities like in CGD or in the STAT1 gene impair important cytokine signaling pathways, hence reducing the strength of the immune response [13,29]. These results highlight the intricate relationship between fungal pathogenicity and host immunity, providing avenues for therapeutic intervention through genetic repair or immune system regulation.

Another serious problem is fungal infections of the central nervous system (CNS), of which cryptococcal meningitis is a well-known example. People with compromised immune systems are disproportionately affected by this deadly illness, especially those who have HIV/AIDS, where it continues to be a major cause of death [17].

Cryptococcus species' capacity to penetrate the blood-brain barrier and cause challenging-to-treat central nervous system infections is a key component of the pathophysiology of cryptococcal meningitis. Even with advancements in antifungal medication, many patients continue to have inadequate treatment outcomes, underscoring the need for better therapeutic approaches and diagnostic instruments in the fight against this crippling illness.

Fungal infections have significant psychological and social effects in addition to physiological ones, which are frequently overlooked. Onychomycosis is one of the chronic or recurrent diseases that has a major impact on patients' quality of life. The stigma attached to obvious fungal symptoms frequently makes the physical suffering brought on by these infections worse, resulting in emotional stress and social exclusion. Furthermore, patients' circumstances may worsen due to the financial strain brought on by protracted and even unsuccessful treatments [27]. A comprehensive strategy that combines dermatological treatment with psychosocial assistance is needed to address these multifaceted problems and give patients comprehensive care that goes beyond treating their physical symptoms.

In conclusion, the spectrum of fungal infections includes both common superficial ailments and severe systemic diseases with high mortality rates. Understanding the diverse clinical presentations, risk factors, and psychosocial consequences of these infections is crucial for improving patient outcomes. Through advancements in diagnostic techniques, the refinement of therapeutic strategies, and the integration of supportive care, the medical community can more effectively address the challenges posed by fungal diseases, both in individual and public health contexts.

Advances in Diagnosis and Treatment

Treating fungal infections effectively requires an early and precise diagnosis. Although they are still useful tools, traditional diagnostic techniques like culturing and histological exams have drawbacks, especially with regard to sensitivity and turnaround time. Even though they are still widely used, contemporary diagnostic techniques provide notable gains in accuracy and speed. Molecular methods that enable the quick and precise identification of fungal species include polymerase chain reaction (PCR)-based testing [14]. Panfungal PCR assays, for example, have demonstrated encouraging outcomes in identifying fungal DNA in blood samples in a few of hours [15]. The choice of the best course of treatment is greatly impacted by this capacity to promptly confirm infection.

The accuracy of diagnosing invasive fungal infections has also increased because to culture-independent diagnostic techniques such assays for the presence of beta-D-glucan and galactomannan. In high-risk patients, galactomannan assays are especially crucial for the diagnosis of invasive aspergillosis. By using these techniques, early disease identification enables quicker management and greatly enhances patient prognosis [16]. Furthermore, the efficacy of infection surveillance can be improved and the chance of diagnostic errors decreased by integrating these contemporary tools with conventional techniques.

The range of available treatments has increased with the creation of novel antifungal drugs. Echinocandins have demonstrated great effectiveness in treating Candida strains that are resistant to other treatments because they work by preventing the formation of fungal cell walls.

Amphotericin B is still the preferred treatment for severe fungal infections in HIV/AIDS patients due to its broad antifungal spectrum. However, newer triazoles like isavuconazole are gaining popularity, offering effective treatment for conditions such as invasive aspergillosis and mucormycosis. Isavuconazole provides faster action and a better safety profile compared to amphotericin B, making it a favorable option, especially for less severe cases. Despite these advancements, amphotericin B remains essential for life-threatening fungal infections [17].

The rise of antifungal drug resistance is complicating the treatment of fungal infections, especially those caused by *Candida*, *Aspergillus*, and *Cryptococcus*. Fungi can resist treatment through mechanisms like changes to drug targets, increased efflux pump activity, and biofilm formation. To combat this, researchers are focusing on developing new antifungal drugs that target distinct fungal structures, while combination therapies are being tested to boost the effectiveness of current treatments. Moreover, antifungal stewardship initiatives are essential to reduce the unnecessary use of antifungals and help manage resistance [16,23]. Antifungal resistance, on the other hand, is becoming a bigger problem. More cases of multidrug resistance in Candida auris, a disease recently identified by the World Health Organization as a global health problem, and Aspergillus resistance to azoles are being reported [18].

Understanding and addressing the growing issue of resistance calls for international cooperation in management and surveillance in addition to innovative therapeutic approaches. The key to solving this issue is keeping an eye on fungal resistance, enforcing stringent antifungal stewardship regulations, and creating novel therapeutic approaches. Additionally, preventing the spread of resistant forms of fungi requires training healthcare professionals in the early detection and management of fungal diseases.

Modern medicines and sophisticated diagnostic technology play an essential role in addressing these issues. The best opportunity for successful therapy, particularly in cases of life-threatening infections, is to combine early and precise diagnosis with carefully chosen antifungal medications. To address the expanding requirements of patients and the difficulties associated with global public health, it is imperative that novel ways be incorporated into clinical practice and that new therapeutic approaches be developed.

New Challenges and Future Directions

Emerging Fungal Infections and High-Risk Populations

The need for attention in high-risk populations is underscored by the advent of novel fungal diseases, including those caused by species of Scedosporium and Lomentospora [19]. Once thought to be uncommon, these bacteria are now frequently responsible for serious infections in people with impaired immune systems. A number of intricate elements, such as urbanization and the acceleration of climate change, are responsible for their formation. Rising temperatures and changed precipitation patterns are two examples of climate change that encourage the spread of fungal diseases to new geographical areas. Diseases such as coccidioidomycosis (valley fever), for example, have begun to spread outside of usual endemic areas, affecting areas that were thought to be immune to this hazard [20]. In consequence, urbanization increases the chance of infection by exposing people to new pathogen habitats.

Intensive Care Units and Infection Control Measures

The growing number of fungal infections in intensive care units (ICUs) emphasizes how important it is to have strict infection control protocols. ICU patients are more susceptible to opportunistic infections because of things like compromised immune systems, invasive procedures, and extended hospital stays. Reducing the spread of illnesses in these settings requires putting in place efficient hygiene procedures, managing hospital transmission, and regularly training medical staff. Significant morbidity and death are linked to invasive fungal infections (IFIs) in intensive care units. Improving patient outcomes requires early diagnosis and suitable therapy. Conventional diagnostic techniques, including blood cultures, frequently have speed and sensitivity issues. Advancements in laboratory tests, including molecular techniques, have been developed to facilitate earlier detection of infections, thereby enabling timely therapeutic interventions [14].

Over the past 20 years, the arsenal of antifungals has grown, providing physicians with a range of treatment options catered to the specific requirements of each patient. These include echinocandins, polyenes, and azoles; each has a unique spectrum of activity and method of action. The management of IFIs still faces difficulties in spite of these developments, especially in light of the rise of resistant strains and the complexity of patient-specific factors in critical care settings [30].

Antifungal Stewardship Programs

Programs for antifungal stewardship are essential for preventing resistance and improving treatment results. These initiatives seek to track patterns of resistance, encourage the proper use of antifungal medications, and create guidelines for empirical treatment [21]. Systematic monitoring of antifungal use prevents the emergence of resistant disease strains and helps cut down on needless treatments. The future of successful treatment of fungal infections depends on the implementation of such programs in healthcare institutions, especially those that use intense pharmacological interventions.

Advances in Immunotherapy

Immunotherapy advancements present encouraging opportunities for more potent therapies of fungal infections. Adoptive T-cell therapy and the use of monoclonal antibodies are two examples that present new opportunities to strengthen the host's immune response against pathogens. Adoptive cell therapy directly boosts the immune response to the infection, whereas monoclonal antibodies can target particular fungal antigens, neutralizing their capacity to colonize and spread. These cutting-edge methods hold great promise for the treatment of patients whose immune systems are too weak to combat infections on their own [32].

Addressing Socioeconomic Factors in Public Health

Public health initiatives must take socioeconomic variables into account in tandem with improvements in medical diagnostic and therapeutic technologies. Because they have less access to healthcare and are more likely to be exposed to environmental factors like air pollution and poor sanitation, marginalized people are frequently at higher risk of developing fungal infections. To reduce risks and enhance health outcomes in these communities, public policy reforms, localized interventions, and health education are essential components [33].

For instance, focused educational initiatives can increase knowledge of the risk factors for fungal infections, promoting early symptom reporting and preventative measures. Infection risks can be further decreased by community interventions, such as initiatives to give access to clean air and water or to better housing conditions. In the end, systemic adjustments are necessary for long-term effects on public health, such as laws that support fair access to medical care and sufficient financing for studies and treatments pertaining to fungal infections [28].

A Holistic Approach to Global Challenges

A thorough and sustainable approach to fungal diseases is crucial for public health in light of global issues like population movement, climate change, and growing treatment resistance in fungi. We can better safeguard the world's healthcare systems and the most vulnerable populations by funding scientific research, education, and creative treatments [34].

Discussion

This review highlights the complex and dynamically evolving nature of fungal infections, which pose significant challenges to both clinical practice and scientific research. While recent years have witnessed notable advances in diagnostics and therapy, substantial barriers remain, such as antifungal resistance and the emergence of new pathogens. Incorporating advanced molecular diagnostic methods into routine clinical practice could significantly improve early infection detection and facilitate the timely initiation of appropriate treatment - critical factors in effectively managing fungal diseases.

Antifungal Resistance: A Growing Concern

One of the most alarming challenges in fungal infections is resistance to antifungal agents, which severely limits available therapeutic options. The increasing number of cases resistant to drugs such as azoles and echinocandins necessitates continuous monitoring of pathogen drug susceptibility and the development of new active substances [23]. Moreover, emerging evidence suggests that specific populations are particularly vulnerable to fungal infections, making these groups a priority for preventive and therapeutic measures.

For example, because of compromised immune responses brought on by persistently high glucose levels and a milieu that supports fungal growth, people with diabetes are far more vulnerable to fungal infections [31]. These patients frequently have infections that are more difficult to cure and call for an all-encompassing therapeutic strategy. In a similar case, fungal respiratory infections are becoming more common among people with long-term conditions like cystic fibrosis. In these situations, fungus such as Aspergillus can worsen the course of underlying illnesses and induce chronic inflammation [22].

The Role of Biofilms in Fungal Pathogenesis

The part biofilms play in fungal pathogenicity is another topic that needs more research. Particularly resistant to antifungal treatments are biofilms, which are intricate structures created by microorganisms on natural or synthetic surfaces. Protective mechanisms such restricted drug penetration through the biofilm matrix, decreased cell metabolism, and the expression of certain resistance genes are thought to be responsible for this resistance [24]. Fungal endocarditis and infections from prosthetic devices are examples of biofilm-associated infections that are very difficult to treat and frequently call for surgery in addition to intensive antifungal medication. Investigating the molecular processes that underlie biofilm development may lead to novel treatment options. For instance, the development of specific medications to interfere with biofilm formation may be made possible by the identification of important signaling pathways. Creating antimicrobial coverings for medical equipment, like catheters or prosthetics, to stop fungal colonization at the patient interface is another promising tactic.

Environmental and Societal Factors

It is important that the environmental and socioeconomic factors influencing the epidemiology of fungal diseases are given due consideration, in conjunction with advancements in diagnosis and treatment. In regions previously considered to be free from harmful fungi, novel infection hotspots are emerging as a consequence of urbanisation and evolving climatic conditions. Concurrently, the risk and burden of fungal infections are further compounded by factors such as unequal access to healthcare and a paucity of health education in underserved populations [28,35].

Comprehensive Approach to Addressing Fungal Infections

In conclusion, improving the management of fungal infections necessitates an all-encompassing strategy that incorporates cutting-edge diagnostics, creative treatments, and preventative measures aimed at the most susceptible groups. While global health and educational initiatives have the potential to increase awareness and lower the prevalence of infections, research into biofilms and resistance mechanisms may produce innovative therapeutic options. The issues presented by fungal risks to health can be effectively addressed by integrating scientific, clinical, and societal initiatives.

Conclusions

Health risks from fungal infections remain considerable, especially for high-risk groups such immunocompromised people, patients receiving rigorous medical treatments, and people living in areas with poor access to healthcare. Numerous issues remain unanswered despite significant advancements in diagnosis and treatment, highlighting the necessity of a thorough and multidimensional approach to addressing this medical condition.

There is promise for quicker and more accurate identification of fungal infections because to recent advancements in diagnostics, such as the creation of molecular methods. Better treatment prospects are also offered by new therapeutic choices, such as targeted therapies and creative antifungal medicines, particularly for infections that are resistant to traditional drugs.

To address the difficulties presented by novel and changing fungal infections, more research in these fields is necessary.

Future research should focus on several key areas:

1. **Development of New Antifungal Agents**

   The growing resistance of pathogens to existing drugs necessitates the development of new antifungal agents. While azoles, echinocandins, and polyenes remain effective in many cases, they are increasingly failing against multi-resistant strains such as *Candida auris* and *Aspergillus fumigatus*. Breakthroughs in this field could emerge from discovering new mechanisms of drug action or identifying fungal-specific molecular targets.

2. **Understanding Mechanisms of Antifungal Resistance**

   Elucidating the mechanisms underlying antifungal resistance is critical for devising strategies to prevent its development. Through genetic adaptation and mutations, fungal pathogens evade the effects of medications, necessitating in-depth studies of their biology and evolution. Research into resistance-associated genes and metabolic pathways can provide valuable insights to inform the design of more effective therapies [23].

3. **Improving Global Surveillance of Fungal Infections**

   Improved global surveillance is essential to better understand the epidemiology of fungal infections. Monitoring transmission patterns, identifying new hotspots and assessing drug resistance trends in different regions is key to effectively planning prevention and treatment activities. Investments in surveillance systems, especially in low-income countries, can facilitate early detection of threats and improve global health protection.

In summary, addressing fungal infections requires not only technological advances in diagnostics and treatment but also broad international collaboration. Further scientific research, improved healthcare infrastructure, and community education are critical components in combating this complex health issue. Through an integrated approach, we can improve the prospects of effectively mitigating the impact of fungal infections on global public health.

Author's contribution

All authors contributed to the article.

Conceptualization: Klimas F, Potoczek A, Pawłowski B;
Methodology: Zatłoka-Mazur D, Rusiński K, Zając P;
Software: Klimas F, Zięba Z, Pudełko I;
Formal analysis: Klimas F, Potoczek A, Pudełko I;
Investigation: Pawłowski B, Sienkiewicz M, Pudełko I;
Resources: Pawłowski B, Sienkiewicz M, Pudełko I;
Data curation: Potoczek A, Rusiński K, Zięba Z;
Writing - rough preparation: Klimas F, Potoczek A, Pawłowski B, Zatłoka-Mazur D;
Writing - review and editing: Zatłoka-Mazur D, Rusiński K, Zając P, Zięba Z;
Visualization: Sienkiewicz M, Rusiński K;
Supervision: Pawłowski B, Zatłoka-Mazur D, Rusiński K;
Project administration: Klimas F, Potoczek A, Pawłowski B, Sienkiewicz M;

All authors have read and agreed with the published version of the manuscript.

Funding statement:
This study has not received any external funding.

Conflict of interest
The authors declare that there is no conflict of interests.

Acknowledgments
The authors have no acknowledgments to report.

Ethical approval
Not applicable.

References

1. The Spectrum of Fungi That Infects Humans Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med. 2014 Nov 3;5(1):a019273. doi: 10.1101/cshperspect.a019273. PMID: 25367975; PMCID: PMC4292074.
2. Garber G. An overview of fungal infections. Drugs. 2001;61 Suppl 1:1-12. doi:10.2165/00003495-200161001-00001.
3. Groll AH, et al. Trends in the postmortem epidemiology of invasive fungal infections. J Infect. 1996;33(1):23-32. doi:10.1016/s0163-4453(96)92700-0.
4. Jaworek AK, et al. Demographic and Pathogen Profiles of Superficial Fungal Infections. Mycoses. 2024;67(12):e70009. doi:10.1111/myc.70009.
5. García-Fontgivell JF, Mayayo Artal E. Prevalence of fungal infections detected from biopsies. Rev Iberoam Micol. 2006;23(4):201-8. doi:10.1016/s1130-1406(06)70045-
6. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis. Clin Microbiol Rev. 2007;20(1):133-63. doi:10.1128/CMR.00029-06.
7. Wald A, et al. Epidemiology of Aspergillus infections in bone marrow transplantation. J Infect Dis. 1997;175(6):1459-66. doi:10.1086/516480.
8. Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep. 2011;3:14. doi:10.3410/M3-14.
9. Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428-38. doi:10.1016/S1473-3099(23)00692-8.
10. Detandt M, Nolard N. Fungal contamination of swimming pool floors. Mycoses. 1995;38(11-12):509-13. doi:10.1111/j.1439-0507.1995.tb00029.x.
11. Friedman DZP, Schwartz IS. Emerging fungal infections: new patterns. J Fungi. 2019;5(3):67. doi:10.3390/jof5030067.
12. Kirkpatrick CH. Chronic mucocutaneous candidiasis. J Am Acad Dermatol. 1994;31(3 Pt 2):S14-7. doi:10.1016/s0190-9622(08)81260-1.

13. Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous disease. Curr Opin Infect Dis. 2012;25(6):658-69. doi:10.1097/QCO.0b013e328358b0a4.
14. Paramythiotou E, et al. Invasive fungal infections in the ICU. Molecules. 2014;19(1):1085-119. doi:10.3390/molecules19011085.
15. Van Burik JA, et al. Panfungal PCR assay for detection of fungal infection in human blood specimens. *J Clin Microbiol.* 1998;36(5):1169-75. doi:10.1128/JCM.36.5.1169-1175.1998.
16. Revie NM, et al. Antifungal drug resistance: mechanisms and impact. Curr Opin Microbiol. 2018;45:70-76. doi:10.1016/j.mib.2018.02.005.
17. Limper AH, et al. Fungal infections in HIV/AIDS. Lancet Infect Dis. 2017;17(11):e334-e343. doi:10.1016/S1473-3099(17)30303-1.
18. Odds FC. Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects. Int J Antimicrob Agents. 1996;6(3):141-4. doi:10.1016/0924-8579(95)00049-6.
19. Horré R, et al. Fungal respiratory infections in cystic fibrosis. Med Mycol. 2010;48 Suppl 1:S1-3. doi:10.3109/13693786.2010.529304.
20. Johnson RH, et al. Coccidioidomycosis: a review. J Investig Med. 2021;69(2):316-323. doi:10.1136/jim-2020-001655. Erratum in: J Investig Med. 2021;69(8):1486. doi:10.1136/jim-2020-001655corr1.
21. Ray A, et al. Antifungal stewardship: What we need to know. Indian J Dermatol Venereol Leprol. 2023;89:5-11. doi:10.4103/ijdvl.IJDVL_957_22.
22. Jain A, et al. Emerging fungal infections among children. J Pharm Bioallied Sci. 2010;2(4):314-20. doi:10.4103/0975-7406.72131.
23. Revie NM, et al. Antifungal drug resistance. Curr Opin Microbiol. 2018;45:70-76. doi:10.1016/j.mib.2018.02.005.
24. Hogan DA, et al. Biofilms and fungal pathogenicity: a multifaceted issue. Nat Rev Microbiol. 2021;19(2):123-138. doi:10.1038/s41579-020-00456-6.
25. Rajasingham R, et al. Cryptococcal meningitis diagnostics and trends. Lancet Infect Dis. 2022;22(4):e112-20. doi:10.1016/S1473-3099(21)00467-8.
26. Le T, et al. Penicillium marneffei infections in HIV patients in Vietnam. Clin Infect Dis. 2011;52(8):945-52. doi:10.1093/cid/cir028.
27. Hay RJ, et al. Psychological impact of superficial fungal infections. Mycopathologia. 2017;182(1):9-15. doi:10.1007/s11046-016-0069-3.
28. Smith DJ, et al. Socio-economic determinants of fungal infections. Public Health Rev. 2020;41(1):15. doi:10.1186/s40985-020-00124-8.
29. Lionakis MS, Netea MG, Holland SM. Mendelian genetics of human susceptibility to fungal infection. *Cold Spring Harb Perspect Med.* 2014 Jun;4(6):a019638. doi:10.1101/cshperspect.a019638. PMID: 24890837; PMCID: PMC4031953.
30. Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med. 2014;4(5):a019703. doi:10.1101/cshperspect.a019703.

31. Casqueiro J, et al. Infections in diabetes mellitus. Indian J Endocrinol Metab. 2012;16(Suppl1):S27-36. doi:10.4103/2230-8210.94253
32. Lum LG, Bollard CM. Specific adoptive T-cell therapy for viral and fungal infections. *Management of Infections in the Immunocompromised Host*. 2018;395–411. doi:10.1007/978-3-319-77674-3_20. PMCID: PMC7121368.
33. Rayens E, et al. Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019. Emerg Infect Dis. 2022;28(10):1955–69. doi:10.3201/eid2810.220391.
34. Smith DJ, et al. Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives. J Fungi (Basel). 2023;9(8):820. doi:10.3390/jof9080820.
35. Rayens E, Rayens MK, Norris KA. An overview of demographic and socioeconomic factors associated with fungal infection risk, United States, 2019. Emerg Infect Dis. 2022 Oct;28(10):1955–69. doi:10.3201/eid2810.220391.